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OBJECTIVE: To estimate the cost effectiveness of treat-
ment with n-3 polyunsaturated fatty acids (n-3 PUFA) for
secondary prevention after myocardial infarction (MI).
METHODS: The cost effectiveness analysis of n-3 PUFA
treatment after MI was based on morbidity and mortal-
ity data and the use of resources obtained prospectively
during the 3.5 years follow-up period of the “GISSI-
Prevenzione study” (Lancet 1999), and the Italian cost
effectiveness study (pharmacoeconomics 2001). The
French patients can be assimilated and compared to the
“GISSI Prevenzione” patients & the patients’ manage-
ment and healthcare resources used have been described
and validated by an expert panel. Two groups were
analysed: treatment with n-3PUFA (n = 2836) versus
treatment without n-3PUFA (n = 2828), the perspective
analysis was French NHS (n-3 PUFA—public price: 1
euro per day). RESULTS: The cost effectiveness analysis
took into account the incremental number of life years
gained (life years gained per patient treated: 0.035) and
the incremental cost of hospital admission, diagnostic test
and drugs, applying a 2.5% discount. The incremental
cost effectiveness ratio for n-3 PUFA in the present sce-
nario was: €18,573 (1999 values). Sensitivity analysis
included the analysis of extremes, producing estimates
varying from €11,680 to €38,720 euros. CONCLUSION:
Since the clinical beneﬁt provided by n-3 PUFA is addi-
tive, this therapy should be added to the established
routine practice, with additive costs. But even so the cost
effectiveness ratio of n-3 PUFA is really reasonable 
taking into account the threshold considered to be accept-
able on an international scale and the other drugs recently
introduced in the routine care of secondary prevention
after MI.
PCV5
COST IMPACT OF AMLODIPINE IN BRITISH
COLUMBIA BASED ON THE PREVENT TRIAL
RESULTS
Ali F1, McKenzie E2, Bruchet R1
1Pﬁzer Canada Inc, Kirkland, QC, Canada; 2Applied
Management,Toronto, ON, Canada
OBJECTIVES: The study objective was to estimate the
savings to the B.C. health care system from reimburse-
ment of amlodipine for patients who have cardiovascular
disease. METHODS: Within the Canadian health care
system, the costs for physician services and hospitaliza-
tions are paid by the provincial health care system.
However, 59% of the costs for prescription drugs are paid
by private payers. PREVENT was a 3-year multicentre
placebo controlled study to test the antiatherogenic effect
of amlodipine in 825 patients with predeﬁned evidence 
of coronary artery disease. Amlodipine was similar to
placebo for angiographic changes but with signiﬁcant
reductions in hospitalizations due to revascularization
and unstable angina. Based on the Canadian prevalence
of cardiovascular disease, 327,000 residents of B.C. may
have CVD. This study assumes these individuals could
beneﬁt from the same advantages and reduction of events
as the subjects in the PREVENT trial. An estimated
122,000 residents would receive partial or full reim-
bursement for amlodipine by the provincial drug plan.
The costs of prescriptions for others would be funded by
private payers. The reduction in hospitalizations related
to CVD events from the PREVENT trial was extrapolated
to the B.C. CVD population. Canadian costs were applied
to estimate the savings for the B.C. health care system.
RESULTS: The cost of amlodipine therapy for eligible
beneﬁciaries of the provincial plan is $70 million annu-
ally; the annual savings to the B.C. health care system
from events avoided is $171 million; with potential
savings of $101 million annually to the B.C. health
system. CONCLUSION: The potential savings to the
B.C. health care system from use of amlodipine in patients
with CVD is up to $101 million annually. This study
demonstrates the signiﬁcant contribution that private
reimbursement of prescription drugs makes to the overall
costs of the Canadian public health care system.
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OBJECTIVES: The clinical trial on cardioversion and
subsequent sinus rhythm maintenance or pharmacologi-
cal ventricular rate control in chronic atrial ﬁbrillation
